Blueprint Medicines PEG Ratio

Blueprint Medicines's peg ratio stands at 121.67. That is above the Healthcare sector average of 11.52. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Blueprint Medicines sits higher the Healthcare benchmark (11.52) with a PEG ratio of 121.67. That is roughly 956.5% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 121.67 is attractive depends on Blueprint Medicines's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Blueprint Medicines's PEG ratio evolved across reporting periods, while the comparison chart places BPMC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, PEG ratio is commonly used to spot outliers. Blueprint Medicines's reading of 121.67 (sector avg 11.52) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.